NCT03210649View on ClinicalTrials.gov

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

April 24, 2017

Study Completion Date

April 24, 2017

Conditions
Dyslipidemia
Interventions
DRUG

CKD-519

Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14

DRUG

Placebo

Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14

Trial Locations (1)

120-752

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY